Docetaxel with or without Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
- Willing and able to provide written informed consent (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed * NOTE: HIPAA authorization may be either included in the informed consent or obtained separately
- Histological or cytological proof of prostate cancer
- Documented progressive metastatic castrate resistant prostate cancer (mCRPC) based on at least one of the following criteria: * PSA progression defined as a minimum of 2 rising PSA levels with a minimum of a 1 week interval between each determination. A minimum PSA of 1.0 ng/mL is required for study entry * Soft-tissue progression defined as an increase >= 20% in the sum of the longest diameter (LD) of all target lesions based on the smallest sum LD since treatment started or the appearance of one or more new lesions * Progression of bone disease (evaluable disease) or two or more new bone lesions by bone scan
- Two or more bone lesions defined by nuclear bone scan
- Eastern Cooperative Oncology Group (ECOG) 0- 1
- Albumin > 30 g/L (within 14 days of randomization)
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 14 days of randomization)
- Hemoglobin >= 10 g/dL (within 14 days of randomization)
- Platelet count >= 100 x 10^9/L (within 14 days of randomization)
- Creatinine =< 1.5 x the institutional upper limit of normal (ULN) (within 14 days of randomization)
- Bilirubin =< ULN (unless documented Gilbert's disease) (within 14 days of randomization)
- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x ULN (within 14 days of randomization)
- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 1.5 x ULN (within 14 days of randomization)
- White blood cell (WBC) count >= 3 x 10^9/L (within 14 days of randomization)
- Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 6 months after the last dose of study drug. Sperm donation is prohibited during the study and for 6 months after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent
- Serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy
- All acute toxic effects of any prior treatment have resolved to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 grade 1 or less
- Willing and able to comply with the protocol, including follow-up visits and examinations
- Received any other investigational therapeutic agents or other anticancer therapies within 2 weeks or 5 half-lives, whichever is shorter, prior to randomization
- Received external beam radiotherapy within the 2 weeks prior to randomization
- Has an immediate need for external beam radiotherapy
- Has received any other systemic investigational or anti-cancer radiopharmaceutical in the past
- Has received any prostate cancer directed chemotherapy in the castration resistant setting
- Has received > 6 prior doses of docetaxel in the castration sensitive setting. Subjects who have received up to 6 prior doses of docetaxel in the castration sensitive setting are permitted if they have not experienced disease progression within 36 weeks of last treatment with docetaxel
- Has received four or more systemic anticancer regimens for mCRPC. Treatment with docetaxel or abiraterone for non-castrate metastatic disease is permissible and does not count towards the lines of therapy for mCRPC. A ‘line’ is a regimen. Combinations of hormones and other types of therapies count as single lines
- Has known grade >= 3 docetaxel-related toxicities or docetaxel toxicity related dose interruption or discontinuation
- Has received blood transfusions or growth factors within the last 4 weeks prior to randomization
- Symptomatic nodal disease (i.e., scrotal, penile, or leg edema)
- Has visceral metastases with > 3 lung and/or liver metastases or individual lesion > 2 cm, as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis within the last 8 weeks prior to randomization
- Symptomatic loco-regional disease that causes ongoing grade 3 or grade 4 urinary or rectal symptoms
- Subjects with a second malignancy with a risk of recurrence > 30% within the next 3 years. Non-melanoma skin cancers, non-invasive bladder cancers, and other in-situ or non-invasive malignancies are permitted while on study
- Has imminent or established cord compression based on clinical findings and/or MRI
- Known bone marrow dysplasia
- Has received any of the following in the 4 weeks prior to randomization: 5-alpha-reductase inhibitors, natural hormonally active foods (e.g., phytoestrogens) or other food supplements known to alter PSA in humans
- Is receiving ongoing treatment with herbal medications that are known in humans to alter PSA or the natural history of prostate cancer. Subjects must discontinue any such herbal medications prior to the first dose of study drug
- Any other serious illness or medical condition that would, in the opinion of the investigator, make this protocol unreasonably hazardous, including but not limited to: * Uncontrolled infection * New York Heart Association (NYHA) III or IV heart failure * Crohn’s disease or those with ulcerative colitis who have not undergone a colectomy * Known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
I. Compare overall survival for subjects treated with docetaxel versus subjects treated with docetaxel plus radium-223.
I. To compare radiographic progression free survival as defined in Prostate Cancer Working Group 3 (PCWG3) criteria.
II. To compare symptomatic skeletal event free survival.
III. To compare time to total alkaline phosphatase (ALP) progression.
IV. To compare on-treatment alterations in quality of life (QOL) as assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), Brief Pain Inventory (BPI), and Brief Fatigue Inventory (BFI) measures between subjects who receive docetaxel with those who receive docetaxel and radium-223.
V. To determine if there is excessive febrile neutropenia in subjects treated with docetaxel plus radium-223.
VI. To determine if there is excessive treatment discontinuation in subjects who are on their fourth line of therapy.
I. To evaluate on treatment alterations in prostate specific antigen (PSA).
II. To evaluate time to first symptomatic skeletal event (SSE).
III. To evaluate on-treatment alterations in bone biomarkers.
IV. To evaluate total ALP response.
V. To evaluate circulating tumor cell (CTC) characterization at baseline and on treatment.
VI. To evaluate CTC response.
VII. To evaluate on-treatment AR-V7 characterization.
VIII. To evaluate on-treatment alterations in circulating tumor deoxyribonucleic acid (ctDNA).
IX. To evaluate on-treatment changes in automated Bone Scan Index (aBSI).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive docetaxel intravenously (IV) on day 1 and prednisone orally (PO) twice daily (BID). Treatment repeats every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive docetaxel IV on day 1 and prednisone PO BID. Treatment repeats every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride via injection on day 1. Treatment with radium Ra 223 dichloride repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, then every 6 months thereafter.
Trial Phase Phase III
Trial Type Treatment
Memorial Sloan Kettering Cancer Center
Michael J. Morris
- Primary ID 18-150
- Secondary IDs NCI-2018-01438
- Clinicaltrials.gov ID NCT03574571